Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

2x300 mg tablets twice daily, for up to 96 weeks

2x300 mg tablets twice daily, for up to 96 weeks

Preferred regimens: 60 to 62 Gy delivered in 20 fractions of 3.0 to 3.1Gy per fraction; 36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction, 2-3 fractions per week

3.6 mg, subcutaneous use

10.8 mg, subcutaneous use

22.5 mg, intramusculair injection

11.25 mg, intramusculair injection

45 mg, subcutaneous use

22.5 mg, subcutaneous use

7.5 mg, subcutaneous use

120 mg, subcutaneous use

80 mg, subcutaneous use

75 mg per square m, IV infusion